Impact Therapeutics’ Selective PARP1 Inhibitor IMP1734 Shows 29.6% Response Rate in Ovarian Cancer at ASCO 2026
Impact Therapeutics (HKG: 7630) presented updated Phase I/II clinical data for IMP1734 (EIK1003), a highly...
Impact Therapeutics
Impact Therapeutics’ Senaparib Cleared by NMPA for Ovarian Cancer Therapy
China-based Impact Therapeutics has announced receiving marketing clearance from the National Medical Products Administration (NMPA)...
Impact Therapeutics Secures $34.5 Million in Series D++ Financing for Senaparib Commercialization
China-based biopharmaceutical company Impact Therapeutics has reportedly secured RMB 250 million (USD 34.5 million) in...
Impact Therapeutics Boosts War Chest with $55.2 Million Series D+ Round for Cancer Drugs
Impact Therapeutics, a biopharmaceutical company based in China, has reportedly secured RMB 400 million (USD...
Huadong Medicine Strikes Exclusive Promotion Deal with Impact Therapeutics for Senaparib in China
China-based Huadong Medicine Co., Ltd (SHE: 000963) has entered into an exclusive market promotion service...
Eikon Therapeutics Inks Licensing Deals and Raises Funds for Drug Pipeline Expansion
US biotech company Eikon Therapeutics has announced three in-licensing deals this week, one of which...
Junshi Biosciences’ Senaparib Meets Primary Endpoint in Phase III Ovarian Cancer Study
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has declared that the Phase III FLAMES study...